Radhakrishnan Maha 4

What Happened
Radhakrishnan Maha, a director of Candel Therapeutics, was granted a derivative award for 32,000 shares on June 23, 2026. The filing reports the award at $0.00 per share (total reported value $0) — this is a grant of equity compensation (an award/option-style derivative), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-23; Filing date: 2026-06-24 (timely).
• Reported amount: 32,000 shares (derivative award) at $0.00 per share; total reported value $0.
• Shares owned after the transaction: not specified in the filing.
• Vesting note: award vests upon the earlier of (i) June 23, 2027 or (ii) the next annual meeting of stockholders; vesting stops if the director resigns or ceases service unless the board decides otherwise.
• Transaction code: A (award/grant); derivative transaction (not an immediate cash transaction).

Context
This was a standard equity award for a board member. As a derivative grant, it gives the holder the right to receive or purchase shares in the future if vesting/exercise conditions are met — it does not represent an immediate market purchase or sale. Such director awards are commonly part of routine compensation and do not, by themselves, signal an intent to buy or sell shares in the open market.